(c) 2024 PillSync.com

Taron-C DHA (ferrous fumarate 53.5 mg iron 38 mg ascorbic acid 25 mg folic acid 1 mg thiamine mononitrate 2 mg riboflavin 3 mg niacin 1.8 mg calcium pantothenate 5 mg pyridoxine hydrochloride 25 mg biotin 300 ug cyanocobalamin 12.5 ug cupric sulfate 2 mg magnesium sulfate 5 ug zinc sulfate 10 mg omega-3 fatty acids 200 mg) Dailymed



IMPRINT: T536     SHAPE: oval
    COLOR: blue

Go PRO for all pill images

Supplement Facts


Other Ingredients: Bovine Gelatin, Glycerin, Yellow Beeswax, Soy Lecithin, Purified Water, Orange Cream Flavor O.S, Sorbitol, Titanium Dioxide, Ethyl Vanillin, FD&C Blue #1.

THIS PRODUCT CONTAINS SOY AND FISH (TUNA, MAY INCLUDE ANCHOVY AND/OR SARDINE).

  Taron™-C DHA is a prescription multivitamin/mineral indicated to provide omega-3 fatty acid supplementation throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. Taron™-C DHA may be useful in improving the nutritional status of women prior to conception.

Contraindications


Taron™-C DHA is contraindicated in patients with a known hypersensitivity to any of the ingredients including soy or fish products. All iron compounds are contraindicated in patients with hemochromatosis, hemosiderosis, or hemolytic anemias.

Warnings


Administration of omega-3 fatty acids should be avoided in patients taking anticoagulants and in those known to have an inherited or acquired predisposition to bleeding.
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

Precautions


Folic acid alone is an improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurologic manifestations remain progressive.

The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered.

Pediatric Use: Safety and effectiveness in pediatric populations have not been established.

Geriatric Use: Safety and effectiveness in elderly populations have not been established.

Biotin levels higher than the recommended daily allowance may cause interference with some laboratory tests, including cardiovascular diagnostic tests (e.g. troponin) and hormone tests, and may lead to incorrect test results. Tell your healthcare provider about all prescription and over-the-counter medicines, vitamins, and dietary supplements that you take, including biotin.

Drug Interactions


Taron™-C DHA is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin, Clopidogrel).

Adverse Reactions


Folic Acid: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Taron™-C DHA after meals may control occasional G.I. disturbances. Taron™-C DHA is best absorbed when taken at bedtime.

Overdosage


Iron is toxic. Acute overdosage of iron may cause nausea and vomiting and, in severe cases, cardiovascular collapse and death. Other symptoms include pallor and cyanosis, melena, shock, drowsiness, and coma. The estimated overdose of orally ingested iron is 300-mg/kg body weight. When overdoses are ingested by children, severe reactions, including fatalities, have resulted. Taron™-C DHA should be stored beyond the reach of children to prevent against accidental iron poisoning.

Treatment: For specific therapy, exchange transfusion and chelating agents should be used. For general management, perform gastric lavage with sodium bicarbonate solution or milk. Administer intravenous fluids and electrolytes and use oxygen.

Description


Taron™-C DHA is a blue, oval softgel capsule containing a dark brown oil, imprinted with “T536”.

Directions For Use


Adults (over 12 years of age) may take one capsule daily between meals or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.

How Supplied


Taron™-C DHA is dispensed in child-resistant bottles of 30 softgel capsules.

PRODUCT CODE 13811-536-30

Storage


Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°- 86°F). [See USP Controlled Room Temperature].

Health Claim Section


KEEP OUT OF REACH OF CHILDREN

For use on the order of a healthcare practitioner.

Call your doctor about side effects. To report side effects, call Trigen Laboratories, LLC at 1-770-509-4500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

                                                                                                                                                   Rev. 12/2021PLR-TARONCDHA-00001-2

Manufactured for:Trigen Laboratories, LLCAlpharetta, GA 30005www.trigenlab.com



Principal Display Panel - 30 Capsule Bottle Label


13811-536-30

Taron ™ -C DHA with Ascorbic Acid Precursors

PRENATAL MULTIVITAMIN SUPPLEMENT

30 CAPSULES

TRIGEN LABORATORIES

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site